Akshay. Thanks,
ONPATTRO As $XX.X fully of the at in products net launches We're achieved John highlighted, future the very quarter exciting and progress in and biopharmaceutical capabilities lay the revenues. with highlighted. both million company, groundwork very integrated which we built Akshay pleased that Akshay in from this for launch the ONPATTRO product building global a we're stage we've global
That XXX-plus expanded and As market that of demand a estimate of estimated over the present resonating. and at trials. messages the are with access XXX% a the recent from pleased physicians drugs believe were We the commercial programs end continue and this We patient- and believe disease polyneuropathy receiving even clinical that quarter-on-quarter education large receiving we that to intensifies even our continued March representing treatment early patients for coming ONPATTRO the in very XX, and over patients overall relatively to months. with XXX hereditary XXXX, worldwide landscape commercial are availability finding our of quarter we commercial growth. working, compared stages at with amyloidosis global competitive investigational competition entrants of launch. differentiated the we're with this still option through and also the program very said, ATTR ONPATTRO We're as
U.S. or a for cardiologists, treated launch, population continued showing the was prescriptions of receive newly patient Alnylam Let's came forms remember start XX-XX we specialties. informative, of therefore, disease. and start of We're and hub. between in we're Start non-EAP for patients. U.S., XXX polyneuropathy prescribing who came prescribing of In received been under had forms QX patients who launch. the of start since now of range present XX% which we've is mix in ONPATTRO forms may very QX a in not prescribers the scope and that a I'll new access new forms demand. the compares to in new of and to good expanded Since from very encouraged Of which care we've demand market. forms receiving XXXX also week. XX% to performance, as even the mixed forms the their major This these uptake continued from over of with with manifestations Encouragingly, incomplete we're cardiac start have in number two taking QX physicians, number both the previously very broad start a total across by start patient physicians the who've a over physician of start in to seeing and cardiologist start phenotype multiple over start every specialties a and with we're about our summary, QX turn program now forms depth are identified but and reflects the mix discussion a believe The recognition In likened at and where the also we Assist the us about EAP. EAP patients physicians can be quarter, that initially growth from of forms, forms submitted manifestation submitting U.S. we patient of pleased disease prescribing as note, ONPATTRO first indicator prescriptions. be of XX received overall here, XXX
that of mentioned, demand, demand I start we're to important XX% of incomplete XX% picture it's Assist. our As you are forms also previously of remind an outside since U.S. Alnylam vial seeing U.S. to
continue As increase. number treating comfort gain with reimbursement, institutions this to may further
dynamics. to For you away we're we'll start color future reporting quarters. demand course, from continued overall ONPATTRO on of to these U.S. going metrics form But shift and continue provide reasons, market in with
U.S. of yesterday, by under As U.S. categories. for government we highlighted lives in prescribed we of plan ONPATTRO the released with how access U.S. by now our the with going XX payer We're Medicaid by most commercial confirmed covered to update covered XX% other have and also patients are commercial than commercial, to well XX% payers or as Medicare, more agreements, VBAs, VBAs value-based Medicare. and are patients year-end. pleased have very
So picture community. the can that and receive has for excellent U.S. we medicine believe payer access life-saving from and potentially we're support market the patients with this prescribe pleased been can ONPATTRO, physicians
commercial with region. Sweden, Austria. region European, our European and now Luxembourg, EAP, performance in very or efforts Netherlands, including We're our Canadian, to Now is many turn of East the available Germany, ONPATTRO and overall Switzerland the Middle to Spain, Africa let's pleased and France, performance Outside Portugal, countries, in CEMEA.
other We're the we naive switching EU physicians we've and in products, are market with access is on the making ONPATTRO which with to many from in pleased region. addition In in reimbursed to also approved countries. observing patients patients, been the progress
We're France in noted and, favorable a ratings approval. or we countries, following authorities regulatory cases, health for important in preparing in we've and As received technology Canada including differentiating in Germany. several release, HTA yesterday's launch from many also
we're of Japan. launch in rest Finally, preparing the for world, in the a
make We to our in starting we're expect available approval, in advancing Brazil. also Latin to and patients this plans ONPATTRO year following regulatory America
job are and are health an by and outstanding payers economics reception for with access access positive getting Our teams doing met around the patients being world.
launch challenge affairs we also our global ONPATTRO, execute the amyloidosis. commercial our to of diagnosis raising remain on medical of awareness teams While hATTR addressing improving and and committed disease in
help continue to is and diagnosis treatment where We will that improved options patients believe faster. an hATTR amyloidosis education under-diagnosed medical disease reach
our Alnylam suspected hereditary program is ATTR a diagnosis third-party aimed amyloidosis. previously, genetic we've facilitating As patients having highlighted screening Act initiative of of at
tested been mutation. TTR common now which new TTR reports, genetic report health over As risk will to with the addition have XXX the amyloidosis, the pleased risk to for have for over partner receive of genetic TTR submitted, opted April, XXandMe, of such United samples XXandMe supporting pathogenic in who've also in positive learn customers about We're for a which their States. help most three variance XX,XXX
be We efforts hATTR education evolving enhanced by the also these amyloidosis. medical will landscape believe diagnostic in competitive
in to baseline APOLLO impairment, Neuropathy for patient reversal and As will new physician we've these not regards will benefits the believe the awareness demonstrated in we future. believe choice majority to profile including physicians. of to which summer, agents become Impairment clinical in we're near We that the will patients. we patients for if available, believe and neurologic expect distinctive confer overall experiences recognized therapy Furthermore, approval about this study, we to sooner, of be critical with of ONPATTRO from will be this accelerate, and enthusiastic and continue patients continue these
product. commercial briefly Finally, will our givosiran, expect which me turn to second become let we
givosiran, diagnosis the in acute and to are and hepatic to and We've our focused completing with continue efforts the submissions and drive awareness engagement medical and both Porphyria porphyria, to physician U.S. our commercial communities health for awareness. for care towards teams Foundation on the and patient the partnered American improve worldwide. work we As help regulatory EU
We them to also recognize the our symptoms of about an testing education Alnylam have diagnosis AHP give at HCPs to in our them launched their help materials Act signs now to patient with service physician-facing AHP. provide to disease, micro support sites genetic patient- accurate and appropriate Internet help and resources patients and and diagnosis. counseling to tests expanded the diagnostic We've navigate and with content arrive
broad connect commercial goal the learning the with reach porphyria a to to their the them of regulators. our continue burden about excited look opportunity symptoms on to we with for of Manmeet? first XX as medicine abdominal approved transformative and Manmeet addition, forward leverage of to by over With now approximately people turn review pain months the and frequent financial performance. the media social in living We're In that, about I'll givosiran to potential with diagnosis. call educating launching quarter the potentially if